Open AccessProbenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro
Author(s) -
Robbins Nathan,
Gilbert Mark,
Kumar Mohit,
McNamara James W.,
Daly Patrick,
Koch Sheryl E.,
Conway Ginger,
Effat Mohamed,
Woo Jessica G.,
Sadayappan Sakthivel,
Rubinstein Jack
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007148
Subject(s) - medicine , ejection fraction , probenecid , cardiology , heart failure , placebo , contractility , pharmacology , pathology , alternative medicine
Transient receptor potential vanilloid 2 is a calcium channel activated by probenecid. Probenecid is a Food and Drug Administration-approved uricosuric drug that has recently been shown to induce positive lusitropic and inotropic effects in animal models through cardiomyocyte transient receptor potential vanilloid 2 activation. The aim of this study was to test the hypothesis that oral probenecid can improve cardiac function and symptomatology in patients with heart failure with reduced ejection fraction and to further elucidate its calcium-dependent effects on myocyte contractility.